Tuesday, September 4, 2012

‘Orphan drug’ used to treat sleep disorders may be a potent cancer-fighting agent used for many malignancies, study finds

›
An inexpensive "orphan drug" used to treat sleep disorders appears to be a potent inhibitor of cancer cells, according to a new ...
Monday, September 3, 2012

Exelixis reports data from cabozantinib phase 3 trial on MTC

›
Exelixis, Inc. reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, l...
Sunday, September 2, 2012

Experimental drug tested against multi-drug resistant TB

›
"Researchers who tested a novel type of antibiotic against multi-drug-resistant tuberculosis [MDR-TB] are reporting that nearly ha...
Saturday, September 1, 2012

GSK and XenoPort receive FDA approval for Horizant® for postherpetic neuralgia

›
GlaxoSmithKline plc  and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Hori...
Friday, August 31, 2012

Combination [of Vismodegib (GDC-0449) and Gemcitabine] therapy may help defeat pancreatic cancer

›
 In continuation of my update on (GDC-0449) Visodegib and Gemcitabine GDC-0449 targets the Smoothened (SMO) protein in the Hedgehog sign...
Thursday, August 30, 2012

Keryx Biopharmaceuticals Announces Top-Line Data from the Perifosine (KRX-0401) X-PECT Phase 3 Clinical Trial

›
Keryx Biopharmaceuticals, Inc. reported today that the Phase 3 "X-PECT" ( X eloda ® + P erifosine E valuation in C olorectal ...
Wednesday, August 29, 2012

Cancer publishes Aeterna Zentaris' perifosine Phase 2 trials in RCC

›
RESULTS: In the Perifosine 228 trial, 1 patient achieved a partial response (objective response rate, 4%; 95% confidence interval, ...
Tuesday, August 28, 2012

Drug shows promise as skin cancer treatment

›
In continuation of my update on Vismodegib Drug shows promise as skin cancer treatment : A new  vismodegib ,  drug for a type of skin ...
Monday, August 27, 2012

Health Canada approves Sunovion’s LATUDA NDA to treat schizophrenia

›
In continuation of my update on Lurasidone .. Health Canada approves Sunovion’s LATUDA NDA to treat schizophrenia : Sunovion Pharma...
Sunday, August 26, 2012

Insomnia Drug Closer to Approval | News | Drug Discovery and Development Magazine

›
Merck & Co. said that its experimental insomnia drug suvorexant (see structure) helped patients fall asleep faster and stay asleep ...
Saturday, August 25, 2012

Two Possible Treatments for Bipolar Disorder Found

›
Researchers at the University of Leeds investigating the genetic causes of bipolar disorder have identified two new drugs – one of which ...
Friday, August 24, 2012

Reformulated Copaxone Meets Goals........

›
Teva Pharmaceutical Industries Ltd. said that a new version of its multiple sclerosis drug Copaxone met its goals in a late-stage clinica...
Thursday, August 23, 2012

New action for ancient heart drug

›
New action for ancient heart drug Since the 13th century, the herb and poisonous plant Foxglove has been used to cleanse wounds an...
Wednesday, August 22, 2012

NEJM hails vismodegib as ‘the greatest advance in therapy yet seen’ for advanced BCC

›
In continuation of my update on Vismodegib NEJM hails vismodegib as ‘the greatest advance in therapy yet seen’ for advanced BCC
Tuesday, August 21, 2012

Promising preliminary data for axitinib in metastatic kidney cancer

›
In continuation of my update on Axitinib Promising preliminary data for axitinib in metastatic kidney cancer : Preliminary study data...